Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 07.09.2026 1 Acta Radiol 1 AJR Am J Roentgenol 1 BMC Cancer 2 Br J Cancer 1 Cancer 1 Endocrinology 2 Eur Urol 2 Int J Radiat Oncol Biol Phys 3 Int J Urol 1 J Magn Reson Imaging 1 J Natl Cancer Inst 4 J Nucl Med 2 J Urol 1 Lancet Oncol 1 Magn Reson Imaging 2 Oncogene 4 Prostate

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Radiol

1. FERREIRA NG, Thomas OMT, Gjesdal KI, Muller S, et al
   Artificial intelligence in prostate MRI: Comparative diagnostic performance in a high-prevalence cohort.
   Acta Radiol. 2026;67:765-774.
   PubMed         Abstract available
   
   

   
   AJR Am J Roentgenol

2. KEANE AB, Navin PJ
   PSMA PET/CT May Play a Role in Prostate Cancer Diagnosis in Patients With Equivocal Results on MRI.
   AJR Am J Roentgenol. 2026 Sep 2. doi: 10.2214/AJR.26.35824.
   PubMed        
   
   

   
   BMC Cancer

3. AMGHAR M, Hielscher T, Rausch T, Ozgur H, et al
   Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [(225)Ac]Ac-/[(177)Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study.
   BMC Cancer. 2026;26:1038.
   PubMed         Abstract available
   
   

   
   Br J Cancer

4. MORILLO AC, Jobre KN, Lendinez Cano G, Blanca-Pedregosa A, et al
   Prospective validation of a urine-based proteomics test for predicting clinically significant prostate cancer in biopsy-naive patients.
   Br J Cancer. 2026 Aug 29. doi: 10.1038/s41416-026-03602.
   PubMed         Abstract available
   
   
5. SHARMA D, McNabb E, Geraghty B, Bailey C, et al
   Evaluation of CNS xenograft brain tumour response to MRI-guided focused ultrasound in combination with radiation therapy.
   Br J Cancer. 2026 Jun 15. doi: 10.1038/s41416-026-03479.
   PubMed         Abstract available
   
   

   
   Cancer

6. LAWRENCE L
   HERMES trial supports shortened SBRT schedule without added toxicity for patients with prostate cancer.
   Cancer. 2026;132:e70538.
   PubMed        
   
   

   
   Endocrinology

7. SEILANI F, Peng J, Wu M, Farahani ME, et al
   BRN2 in Lineage Plasticity: A Prostate Cancer-Focused Perspective.
   Endocrinology. 2026 Sep 3:bqag102. doi: 10.1210.
   PubMed         Abstract available
   
   

   
   Eur Urol

8. FOSSATI N, Montorsi F, Stenzl A, Penson D, et al
   Optimizing Quality-of-life Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer.
   Eur Urol. 2026 Sep 1:S0302-2838(26)02344-4. doi: 10.1016/j.eururo.2026.
   PubMed        
   
   
9. ZAURITO P, Gandaglia G, Montorsi F
   Re: Robert M. Meier, Nima Aghdam, Alan C. Beckman, et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.029.
   Eur Urol. 2026 Sep 1:S0302-2838(26)02348-1. doi: 10.1016/j.eururo.2026.
   PubMed        
   
   

   
   Int J Radiat Oncol Biol Phys

10. MURRAY NZ, Sokeye J, Horns JJ, Chipman J, et al
    Use of Hypofractionation Among Underserved Populations Undergoing Radiation Therapy for Cancer: Implications for Policy.
    Int J Radiat Oncol Biol Phys. 2026;126:301-307.
    PubMed         Abstract available
    
    
11. COTE N, Sun L, Nagar H, Brennan V, et al
    Simulation-Free Adaptive Prostate Stereotactic Body Radiation Therapy on Magnetic Resonance-Linac: Technical Feasibility and Clinical Experience.
    Int J Radiat Oncol Biol Phys. 2026;126:533-543.
    PubMed         Abstract available
    
    

    
    Int J Urol

12. KOBAYASHI S
    Editorial Comment to Validation of the NCCN Subclassification for Intermediate-Risk Prostate Cancer in a Japanese Radical Prostatectomy Cohort: Results From the MICAN Study.
    Int J Urol. 2026;33:e70629.
    PubMed        
    
    
13. HORI T, Iwamoto H, Inaba T, Nakagawa R, et al
    Comparative Prognostic Impact of Two-Dimensional and Three-Dimensional Computed Tomography-Based Sarcopenia Indices in Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2026;33:e70627.
    PubMed         Abstract available
    
    
14. IKEDA J, Taniguchi H, Inoue M, Masuo Y, et al
    Distinct Prognostic Roles of Grade Group and Intraductal Carcinoma of the Prostate in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.
    Int J Urol. 2026;33:e70630.
    PubMed         Abstract available
    
    

    
    J Magn Reson Imaging

15. ZU Z
    Editorial for "Accuracy of Quantitative Chemical-Exchange-Saturation-Transfer Imaging for Grading Prostate Cancer and Predicting Adverse Pathology".
    J Magn Reson Imaging. 2026 Sep 1. doi: 10.1002/jmri.70536.
    PubMed        
    
    

    
    J Natl Cancer Inst

16. LEAPMAN MS, Wang R, Sprenkle PC, Kim IY, et al
    Association between genomic classifier scores and initial management of localized prostate cancer in the United States.
    J Natl Cancer Inst. 2026 Aug 31:djag247. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

17. HASENAUER N, Probst C, Schloetelburg W, Jedamzik T, et al
    Overall Survival with [(177)Lu]Lu-PSMA-617 Versus [(177)Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.
    J Nucl Med. 2026;67:1440-1447.
    PubMed         Abstract available
    
    
18. FAROLFI A, Sgro CMP, Brusa I, Dall'Olio D, et al
    PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.
    J Nucl Med. 2026 Jul 2:jnumed.126.272108. doi: 10.2967/jnumed.126.272108.
    PubMed         Abstract available
    
    
19. KUMAR R, Ram A, Kumar S, Singh H, et al
    PCa Detection in PI-RADS 4 and 5 Lesions: Comparison of [(68)Ga]Ga-PSMA-11 PET/CT-Guided Robot-Assisted Biopsy Versus mpMRI Cognitive-Fusion TRUS-Guided Prostate Biopsy.
    J Nucl Med. 2026 Jun 18:jnumed.126.272036. doi: 10.2967/jnumed.126.272036.
    PubMed         Abstract available
    
    
20. JALLINOJA VIJ, Mun JS, Campanella A, Sasson A, et al
    Nonsteroidal (18)F-Labeled PET Tracer for Imaging Androgen Receptors.
    J Nucl Med. 2026 Jun 11:jnumed.125.271531. doi: 10.2967/jnumed.125.271531.
    PubMed         Abstract available
    
    

    
    J Urol

21. MASUR J, Viscuse PV, Dreicer R
    Refining the Roadmap: Practical Insights on the 2026 AUA/SUO Advanced Prostate Cancer Amendment.
    J Urol. 2026 Sep 3:101097JU0000000000005295. doi: 10.1097/JU.0000000000005295.
    PubMed        
    
    
22. QIAN Z, Radhakrishnan A, Borza T
    Reaching the Unreached: Electronic Decision Aids and the Engagement Gap in Prostate Cancer Screening.
    J Urol. 2026 Sep 2:101097JU0000000000005289. doi: 10.1097/JU.0000000000005289.
    PubMed        
    
    

    
    Lancet Oncol

23. BOURKE L, Rosario DJ, Reale S, Ibeggazene S, et al
    An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.
    Lancet Oncol. 2026 Sep 4:S1470-2045(26)00304.
    PubMed         Abstract available
    
    

    
    Magn Reson Imaging

24. WANG Z, Zang Z, Li Y, Huang Z, et al
    Water-exchange pharmacokinetic modeling improves DCE-MRI for ROI-based assessment of prostate lesions and of clinically significant prostate cancer.
    Magn Reson Imaging. 2026;134:110778.
    PubMed         Abstract available
    
    

    
    Oncogene

25. LEO J, Chen F, Shi W, Liang X, et al
    Enhancing the efficacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deficient tumors by inducing ferroptosis.
    Oncogene. 2026;45:3753-3764.
    PubMed         Abstract available
    
    
26. PEREGO M, Madzo J, Kossenkov AV, Atilgan FC, et al
    Neuromedin U 'innervation' reprograms myeloid immunosuppression in neuroendocrine prostate cancer.
    Oncogene. 2026 Sep 1. doi: 10.1038/s41388-026-03969.
    PubMed         Abstract available
    
    

    
    Prostate

27. MILLAN B, Kenigsberg AP, Hesswani C, Koller CR, et al
    Long-Term Oncologic Outcomes of Neoadjuvant Tumor-Directed Immunotherapy (PROSTVAC) Before Radical Prostatectomy for Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Trial.
    Prostate. 2026 Aug 31. doi: 10.1002/pros.70224.
    PubMed         Abstract available
    
    
28. AGRAWAL R, Parghane RV, Joshi A, Prabhash K, et al
    Evaluation of [(225)Ac]Ac-PSMA-617 vis-a-vis Rechallenge [(177)Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.
    Prostate. 2026;86:1443-1455.
    PubMed         Abstract available
    
    
29. CANBOLAT MZ, Dagli I, Uzel T, Cayirli A, et al
    A Triple Clinical Filter Model for Selective Omission of Systematic Cores in Transperineal Cognitive Prostate Biopsy: A Retrospective Observational Study.
    Prostate. 2026;86:1421-1427.
    PubMed         Abstract available
    
    
30. FREEDLAND AR, Moriera DM, Gong J, Freedland SJ, et al
    Black Race Predicts Poor Compliance and Higher Prostate Cancer Risk in a Multinational Repeat Biopsy Cohort: Secondary Analysis From the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Clinical Trial.
    Prostate. 2026 Aug 31. doi: 10.1002/pros.70241.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum